Lexicon Pharmaceuticals (LXRX) Total Debt (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Total Debt data on file, last reported at $49.7 million in Q1 2026.

• On a quarterly basis, Total Debt fell 50.66% year-over-year to $49.7 million in Q1 2026; TTM through Mar 2026 was $49.7 million, a 50.66% decrease from a year earlier, with the FY2025 full-year figure at $54.0 million, down 46.16% from the prior year.
• Total Debt for Q1 2026 stood at $49.7 million, down from $54.0 million in the prior quarter.
• Over the last five years, Total Debt for LXRX reached as high as $100.7 million in Q1 2025 and fell as low as $23.5 million in Q1 2022.
• Historically, Total Debt has averaged $69.6 million across 5 years, with a median of $56.5 million in 2025.
• Across the five-year window, Total Debt jumped 318.64% in 2023 and tumbled 50.66% in 2026, its largest moves.
• Year by year, Total Debt stood at $48.6 million in 2022, then jumped by 104.84% to $99.5 million in 2023, then advanced by 0.79% to $100.3 million in 2024, then tumbled by 46.16% to $54.0 million in 2025, then slipped by 8.0% to $49.7 million in 2026.
• Per Business Quant data, the three most recent Total Debt figures were $49.7 million in Q1 2026, $54.0 million in Q4 2025, and $56.5 million in Q3 2025.